Safety of Urate-Lowering Therapies Managing the Risks to Gain the Benefits

被引:15
|
作者
Keenan, Robert T. [1 ,2 ,3 ]
机构
[1] Duke Specialty Infus Ctr, Duke Gout & Crystal Arthropathies Clin, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
关键词
Gout; Allopurinol; Febuxostat; Pelgoticase; Safety; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; PRACTICE RESEARCH DATABASE; US GENERAL-POPULATION; SERUM URATE; HYPERSENSITIVITY SYNDROME; CARDIOVASCULAR-DISEASE; PLASMA OXYPURINOL; ADVERSE-REACTIONS; XANTHINE-OXIDASE;
D O I
10.1016/j.rdc.2012.08.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gout is a metabolic disorder of purine metabolism and uric acid elimination. Over time, acute gout can develop into a chronic, disabling arthropathy, often associated with multiple comorbidities. Gout patients have often been undertreated, partly because of the clinician's perceived risks of a therapy outweighing its potential benefits. The approval of new therapies to treat hyperuricemia in gout has led to a new understanding of gout management and medication safety regarding new and old therapies. This review focuses on potential safety issues of currently available urate-lowering therapies and outlines strategies to minimize risks so their benefits can be reached.
引用
收藏
页码:663 / +
页数:19
相关论文
共 50 条
  • [1] Update on emerging urate-lowering therapies
    Chohan, Saima
    Becker, Michael A.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (02) : 143 - 149
  • [2] Adherence with urate-lowering therapies for the treatment of gout
    Leslie R Harrold
    Susan E Andrade
    Becky A Briesacher
    Marsha A Raebel
    Hassan Fouayzi
    Robert A Yood
    Ira S Ockene
    Arthritis Research & Therapy, 11
  • [3] Expert opinion on emerging urate-lowering therapies
    Stamp, Lisa K.
    Merriman, Tony R.
    Singh, Jasvinder A.
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (03) : 201 - 209
  • [4] Adherence with urate-lowering therapies for the treatment of gout
    Harrold, Leslie R.
    Andrade, Susan E.
    Briesacher, Becky A.
    Raebel, Marsha A.
    Fouayzi, Hassan
    Yood, Robert A.
    Ockene, Ira S.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
  • [5] Adherence and persistence to urate-lowering therapies in the Irish setting
    Bernie McGowan
    Kath Bennett
    Carmel Silke
    Bryan Whelan
    Clinical Rheumatology, 2016, 35 : 715 - 721
  • [6] Surprising safety outcomes of urate-lowering therapy
    McHugh, Jessica
    NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (06) : 320 - 320
  • [7] Adherence and persistence to urate-lowering therapies in the Irish setting
    McGowan, Bernie
    Bennett, Kath
    Silke, Carmel
    Whelan, Bryan
    CLINICAL RHEUMATOLOGY, 2016, 35 (03) : 715 - 721
  • [8] Influence of urate-lowering therapies on renal handling of uric acid
    Lili Ma
    Lei Wei
    Huiyong Chen
    Zhuojun Zhang
    Qiang Yu
    Zongfei Ji
    Lindi Jiang
    Clinical Rheumatology, 2016, 35 : 133 - 141
  • [9] Influence of urate-lowering therapies on renal handling of uric acid
    Ma, Lili
    Wei, Lei
    Chen, Huiyong
    Zhang, Zhuojun
    Yu, Qiang
    Ji, Zongfei
    Jiang, Lindi
    CLINICAL RHEUMATOLOGY, 2016, 35 (01) : 133 - 141
  • [10] Cardiovascular Safety of Urate Lowering Therapies
    Eun Ha Kang
    Seoyoung C. Kim
    Current Rheumatology Reports, 2019, 21